CureVac (NASDAQ:CVAC - Get Free Report)'s stock had its "market outperform" rating reiterated by equities research analysts at JMP Securities in a note issued to investors on Friday,Benzinga reports. They currently have a $16.00 target price on the stock. JMP Securities' target price suggests a potential upside of 354.55% from the stock's previous close.
CureVac Price Performance
Shares of NASDAQ CVAC traded down $0.13 during midday trading on Friday, hitting $3.52. The company had a trading volume of 914,703 shares, compared to its average volume of 1,006,651. The firm has a market capitalization of $788.06 million, a price-to-earnings ratio of 6.40 and a beta of 2.51. CureVac has a twelve month low of $2.21 and a twelve month high of $5.28. The business has a 50-day simple moving average of $3.63 and a two-hundred day simple moving average of $3.21. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.
Institutional Investors Weigh In On CureVac
Several institutional investors have recently modified their holdings of the company. Private Advisor Group LLC acquired a new position in CureVac during the third quarter worth $30,000. International Assets Investment Management LLC purchased a new position in shares of CureVac in the third quarter valued at $35,000. Integrated Wealth Concepts LLC acquired a new position in shares of CureVac during the 3rd quarter worth $35,000. Two Sigma Advisers LP purchased a new stake in shares of CureVac in the 4th quarter worth about $48,000. Finally, Jump Financial LLC acquired a new stake in CureVac in the 4th quarter valued at about $55,000. Hedge funds and other institutional investors own 17.26% of the company's stock.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
See Also
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
